<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Gurdon Institute</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/78F0169A-7CD6-4D5E-B67E-499A4D67A502"><gtr:id>78F0169A-7CD6-4D5E-B67E-499A4D67A502</gtr:id><gtr:firstName>Frederick</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Livesey</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002501"><gtr:id>793BD289-E306-469C-A9F8-9154D25BAE8D</gtr:id><gtr:title>Application of a human stem cell model of early Alzheimers disease pathology to drug discovery and testing</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1002501</gtr:grantReference><gtr:abstractText>Dementia is a brain disease in older people which starts with memory loss and progresses to severe problems with thinking, learning and carrying out simple daily tasks, including feeding yourself and recognising friends and family. Most people diagnosed with dementia die less than 10 years after diagnosis. In dementia, brain cells malfunction in the early stages of the disease and then start to die off. Alzheimer s disease, named after the man who described it 100 years ago, is the commonest form of dementia worldwide, and accounts for about two thirds of dementia cases. Currently, there are no medicines that slow down or cure any type of dementia. One reason for this is that only humans get dementia, so giving animals like mice a type of dementia that looks and acts like the human disease is difficult. If other animals got dementia, we would be able to study the disease in them and develop new drugs to treat the disease. To get around this problem, we have come up with a way to grow human brain cells in the lab, by turning a person s own skin cells into the brain cells that are affected by Alzheimer s disease. We ve used this to make brain cells that get a type of Alzheimer s disease, by making brain cells from people who were born with Down syndrome, the commonest cause of mental retardation in the world. Unfortunately, most adults with Down syndrome also get Alzheimer s disease, because they have an extra copy of one of the genes that can cause Alzheimer s disease. The Down syndrome brain cells get sick in the lab in a way that is very similar to what we see in the brains of people with Alzheimer s disease, but they do it in months instead of decades. When we feed the brain cells with drugs that are being developed to treat Alzheimer s disease, we stop the development of the disease. We are now using these cells to find new drugs that can slow down the disease, as a first step to going on to test them in people with Alzheimer s.</gtr:abstractText><gtr:technicalSummary>There are currently no disease-modifying drugs in clinical use for Alzheimer?s disease (AD), of which there are 25 million cases worldwide. A human model of AD will be very useful for research and drug development, to complement available animal models. Any relevant disease model must use the cell type affected by the disease, and develop pathology on a useful timescale. To solve both of those problems, we developed a process to differentiate human pluripotent stem cells to cerebral cortex neurons, the part of the brain affected in AD. To model early stage Alzheimer?s disease, we used this process to generate cortical neurons from Down syndrome iPS cells (DS-iPS). Adults with Down syndrome develop early-onset Alzheimer?s disease, primarily due to increased expression of the amyloid precursor protein on chromosome 21. A key step in the development of Alzheimer?s disease in vivo is the increased generation and accumulation of the pathogenic Abeta42 peptide fragment of APP in the cerebral cortex. The generation of Abeta42, the formation of amyloid plaques and neuronal cell death occur in our system over a period of months, compared to typically several decades in vivo. Production of Abeta42 is abolished in this system by known gamma secretase inhibitors, demonstrating the utility of this system for identifying disease-modifying compounds. We propose to use this DS-iPS model of early-onset AD as an in vitro platform for screening and identifying compounds that alter Abeta production and accumulation and Abeta42-mediated cell death, using libraries of known bioactive molecules. This will both demonstrate the utility of systems such as this for disease modelling and drug testing/discovery, but also identify novel candidate disease-modifying compounds.</gtr:technicalSummary><gtr:fund><gtr:end>2014-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>711321</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>EU IMI consortium</gtr:description><gtr:id>0818661A-85B2-4C64-9CA0-734DB807EF34</gtr:id><gtr:impact>Consortium initiated in October 2012</gtr:impact><gtr:outcomeId>EJTtDp8rzUb-1</gtr:outcomeId><gtr:partnerContribution>A multicentre, public-private partnership to develop stem cell models for drug screening in several disease areas, including neurology.</gtr:partnerContribution><gtr:piContribution>Participating member in the StemBANCC consortium, headed by the University of Oxford.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Department of Health/BIS dementia meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E2809AAB-326E-45C9-82BC-A30C119ABFDE</gtr:id><gtr:impact>Input/presentation into DoH dementia research strategy

Raised profile of research strategy for dementia drug discovery</gtr:impact><gtr:outcomeId>5464b7695996d4.66243108</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>370000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AstraZeneca Research Funding</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>CB2775AE-90BA-4E48-8B3F-4B35E1FC014D</gtr:id><gtr:outcomeId>5464b6201e26c0.99691007</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1525000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Dementia Platform UK</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0A4E7625-41EF-4EF6-9636-79C0DF52DCD7</gtr:id><gtr:outcomeId>5481a429d29324.00723830</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1970000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stem Cell Centre</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>5E851479-C2D7-4F61-819E-E49CC277BD93</gtr:id><gtr:outcomeId>5481a38f2d2249.97365285</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>27EC739A-4D09-4D7E-9D3F-0225BBC43679</gtr:id><gtr:outcomeId>exNq31EzmVV</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Knowledge on process development for drug discovery platform, using stem cell models, informed our technical approaches in setting up a new biotech company, Talisman Therapeutics</gtr:description><gtr:grantRef>G1002501</gtr:grantRef><gtr:id>53980BD8-B9F6-4831-B70E-451F32C1DD33</gtr:id><gtr:impact>Considerable pharma collaboration and partnering with our biotech company</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>5464b7ee797330.52347794</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Methods for drug discovery in human stem cell systems</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Human cerebral cortex neurons generated from patient-derived stem cells that replay Alzheimer's disease pathogenesis in vitro.</gtr:description><gtr:id>C6342BA7-3C66-4FA2-9CF0-5B7AA3E9F1F8</gtr:id><gtr:impact>Proof of concept that contributed to setup and funding of IMI consortium, StemBANCC</gtr:impact><gtr:outcomeId>54a28e318574e5.90104351</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Stem cell models of dementia</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Talisman Therapeutics Ltd</gtr:companyName><gtr:description>Talisman Therapeutics is a human stem cell drug discovery company, based in Cambridge UK. We are committed to revolutionising the discovery of treatments for Alzheimer's disease (AD).</gtr:description><gtr:id>8122567C-9475-4E13-898E-BFD85ECCA93C</gtr:id><gtr:impact>Currently have multiple collaborations with large pharma.</gtr:impact><gtr:outcomeId>5464b8bf0deb46.84926926</gtr:outcomeId><gtr:url>http://www.talisman-therapeutics.com</gtr:url><gtr:yearCompanyFormed>2013</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>201A01AA-298A-48BF-AADA-FDD3D3CA250B</gtr:id><gtr:title>Stem cell models of Alzheimer's disease and related neurological disorders.</gtr:title><gtr:parentPublicationTitle>Alzheimer's research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0115e28ec093787ef4d1ac15c73df40"><gtr:id>f0115e28ec093787ef4d1ac15c73df40</gtr:id><gtr:otherNames>Livesey FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_16013_23_23131128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11A527CE-AFB7-47A4-9B7F-688CE55AB1FC</gtr:id><gtr:title>A human stem cell model of early Alzheimer's disease pathology in Down syndrome.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd91fa878c05d52bd7c1e3a21e702619"><gtr:id>fd91fa878c05d52bd7c1e3a21e702619</gtr:id><gtr:otherNames>Shi Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>doi_16013_ed_3003771</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002501</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>